

Ignacio Duran

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1711321/ignacio-duran-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

6,538
citations

37
h-index

79
g-index

178
ext. papers

8,720
ext. citations

5.5
avg, IF

5.54
L-index

#	Paper	IF	Citations
160	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.. <i>Lancet Oncology, The, 2022,</i>	21.7	7
159	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.. <i>Lancet Oncology, The, 2022,</i>	21.7	5
158	Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum: A feasibility study.. <i>Journal of Clinical Oncology, 2022,</i> 40, 538-538	2.2	
157	Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab + ipilimumab in the TITAN-RCC phase 2 trial.. <i>Journal of Clinical Oncology, 2022,</i> 40, 367-367	2.2	
156	Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.. <i>Journal of Clinical Oncology, 2022,</i> 40, 490-490	2.2	
155	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology, 2022,</i>	10.2	2
154	Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management.. <i>Critical Reviews in Oncology/Hematology, 2022,</i> 103683	7	0
153	Gold Glyconanoparticles Combined with 91B9 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors. <i>Cancers, 2022,</i> 14, 2413	6.6	1
152	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus, 2021,</i> 7, 1084-1091	5.1	0
151	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>New England Journal of Medicine, 2021,</i> 384, 1125-1135	59.2	110
150	Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.. <i>Journal of Clinical Oncology, 2021,</i> 39, 4577-4577	2.2	
149	Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).. <i>Journal of Clinical Oncology, 2021,</i> 39, e16555-e16555	2.2	
148	Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).. <i>Journal of Clinical Oncology, 2021,</i> 39, 4576-4576	2.2	5
147	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology, 2021,</i> 39, 1553-1562	2.2	13
146	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology, 2021,</i> 4, 456-463	6.7	4
145	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology, 2021,</i> 4, 464-472	6.7	9
144	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. <i>European Urology, 2021,</i> 80, 7-11	10.2	12

143	Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. <i>Clinical and Translational Oncology</i> , 2021 , 23, 58-64	3.6	1
142	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. <i>Clinical and Translational Oncology</i> , 2021 , 23, 882-891	3.6	1
141	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021 , 128, 196-205	5.6	3
140	Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 393-393	2.2	5
139	Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 336-336	2.2	
138	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1165-1178	3.8	2
137	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
136	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2020 , 21, 61-68	0.9	0
135	MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 640.e23-640.e29	2.8	2
134	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
133	Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1135-1148	6.2	11
132	Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3055-3055	2.2	1
131	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5012-5012	2.2	21
130	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5015-5015	2.2	10
129	Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 511-511	2.2	6
128	MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 541-541	2.2	
127	ECO Experts Consensus on establishing renal cancer healthcare quality measures in Spain.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 220-220	2.2	
126	Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 95-95	2.2	0

125	Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17582-e17582	2.2	2
124	Expert consensus on the development of quality care measures for kidney cancer in Spain.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19180-e19180	2.2	
123	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102978	7	39
122	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020 , 204, 63-70	2.5	11
121	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. <i>European Urology</i> , 2020 , 77, 269-276	10.2	24
120	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 1208-1216	6.4	37
119	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1574-1588	21.7	115
118	697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). <i>Annals of Oncology</i> , 2020 , 31, S550-S551	10.3	11
117	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) 2019 , 7, 20		50
116	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019 , 76, 73-81	10.2	74
115	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1370-1385	21.7	343
114	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 381, 338-348	59.2	456
113	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019 , 25, 1706-1714	50.5	193
112	DUTRENEO Trial: A phase II randomized trial of DURvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4588-TPS4588	2.2	5
111	Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastatic castration-resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 198-198	2.2	0
110	Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 365-365	2.2	1
109	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 550-550	2.2	2
108	EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS497-TPS497	2.2	10

107	A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS501-TPS501	2.2	2
106	FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 411-411	2.2	
105	Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4522-4522	2.2	2
104	A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5040-5040	2.2	1
103	Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. <i>Journal of Urology</i> , 2019 , 202, 742-747	2.5	1
102	Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer. <i>Clinical and Translational Oncology</i> , 2019 , 21, 796-804	3.6	8
101	Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study. <i>European Journal of Haematology</i> , 2018 , 100, 479-487	3.8	6
100	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018 , 73, 462-468	10.2	23
99	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 748-757	4.0	753
98	Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. <i>BMC Cancer</i> , 2018 , 18, 561	4.8	9
97	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4503-4503	2.2	42
96	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4506-4506	2.2	62
95	The application of cognitive computing technology in genomics in precision oncological medicine: The Sistemas Genomicos Experience.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18544-e18544	2.2	1
94	Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 409-409	2.2	22
93	Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 411-411	2.2	21
92	Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer 2018 , 91-98		
91	A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4593-TPS4593	2.2	2
90	The continuing role of chemotherapy in the management of advanced urothelial cancer. <i>Therapeutic Advances in Urology</i> , 2018 , 10, 455-480	3.2	11

89	Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. <i>International Journal of Cancer</i> , 2018 , 143, 1954-1962	7.5	13
88	Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. <i>European Journal of Cancer Care</i> , 2017 , 26, e12452	2.4	12
87	Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. <i>Clinical and Translational Oncology</i> , 2017 , 19, 173-179	3.6	2
86	The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 217-226	3.5	4
85	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. <i>Annals of Oncology</i> , 2017 , 28, 1508-1516	10.3	166
84	Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	7
83	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017 , 389, 67-76	4.0	1171
82	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection 2017 , 5, 71		77
81	Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. <i>OncoTargets and Therapy</i> , 2017 , 10, 4885-4893	4.4	4
80	Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective. <i>Annals of Oncology</i> , 2017 , 28, v303	10.3	2
79	Systemic treatment of renal cell cancer: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2017 , 60, 77-89	14.4	81
78	Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel -Activating Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1310-1315	7.3	13
77	Biomarkers of response to PD-1/PD-L1 inhibition. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 116, 116-124	7	185
76	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. <i>Targeted Oncology</i> , 2017 , 12, 19-35	5	57
75	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 323-323	2.2	1
74	The role of microRNAs (miRNAs) as predictive biomarker in advanced renal cell carcinoma (mRCC) patients (pts) with Extreme response to tyrosine kinase inhibitors (TKIs) treatment.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 470-470	2.2	1
73	Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 106551-106564	3.3	10
72	Neuroendocrine Carcinoma 2017 , 3052-3057		

71	Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 437-437	2.2	
70	SEOM clinical guidelines for the management of germ cell testicular cancer (2016). <i>Clinical and Translational Oncology</i> , 2016 , 18, 1187-1196	3.6	9
69	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA4500-LBA4500	2.2	2
68	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA4500-LBA4500	2.2	13
67	Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): The ABIFOOD trial (EudraCt number: 2012-003226-25).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 227-227	2.2	2
66	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5058-5058	2.2	
65	Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUG) study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4571-4571	2.2	
64	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. <i>Pharmacogenomics</i> , 2016 , 17, 463-71	2.6	5
63	Análisis del impacto presupuestario de denosumab para la prevención de eventos relacionados con el esqueleto en adultos con metástasis óseas de tumores sólidos en España. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2015 , 12, 83-92		
62	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). <i>Annals of Oncology</i> , 2015 , 26, 1987-1993	10.3	85
61	Immunotherapy in prostate cancer: review of the current evidence. <i>Clinical and Translational Oncology</i> , 2015 , 17, 339-57	3.6	25
60	Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. <i>European Urology</i> , 2015 , 67, 740-9	10.2	129
59	JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or metastatic transitional-cell carcinoma (mTCC), who progressed before 12 months after cisplatin-based chemotherapy: A Spanish Oncologic Genitourinary Group (SOGUG) study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4525-4525	2.2	1
58	Prognostic significance of thromboembolic events in chemotherapy-treated germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4536-4536	2.2	2
57	Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15601-e15601	2.2	2
56	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment: ABIDO-SOGUG Trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1199-1199	2.2	1
55	Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 167-167	2.2	1
54	Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TP65073-TP65073	2.2	

53	Safety of cabazitaxel (Cbz) in patients (pt) with metastatic transitional-cell carcinoma (mTCC) progressing to cisplatin-based chemotherapy: Results from the JEVTC-C-SOGUG Study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15537-e15537	2.2	
52	Quality of life assessment in patients with advanced renal cancer: CAVIREN study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20654-e20654	2.2	0
51	Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014 , 32, 644-52	4.3	1
50	Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. <i>Clinical and Translational Oncology</i> , 2014 , 16, 322-9	3.6	16
49	A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. <i>European Urology</i> , 2014 , 65, 516-20	10.2	41
48	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. <i>European Journal of Cancer</i> , 2014 , 50, 3145-52	7.5	82
47	Simulation and modelling of the waves transmission and generation in a stator blade row in a combustion-noise framework. <i>Journal of Sound and Vibration</i> , 2014 , 333, 6090-6106	3.9	17
46	Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. <i>SpringerPlus</i> , 2014 , 3, 328		12
45	Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Subgroup analysis from a prospective multinational study. <i>Molecular and Clinical Oncology</i> , 2014 , 2, 701-708	1.6	8
44	Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study. <i>Journal of Clinical Medicine</i> , 2014 , 3, 883-96	5.1	8
43	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 361-72	4.1	26
42	SEOM clinical guidelines for the treatment of renal cell carcinoma. <i>Clinical and Translational Oncology</i> , 2014 , 16, 1043-50	3.6	24
41	Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries. <i>Journal of Bone Oncology</i> , 2014 , 3, 40-8	4.5	36
40	Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4588-4588	2.2	5
39	Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02) Interim analysis on safety.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 359-359	2.2	3
38	Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 425-425	2.2	5
37	Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16034-e16034	2.2	
36	Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5096-TPS5096	2.2	

35	Dural metastases in advanced prostate cancer: a case report and review of the literature. <i>Current Urology</i> , 2013 , 7, 166-8	1.7	9
34	Solution of the quasi-one-dimensional linearized Euler equations using flow invariants and the Magnus expansion. <i>Journal of Fluid Mechanics</i> , 2013 , 723, 190-231	3.7	92
33	Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). <i>European Journal of Cancer</i> , 2013 , 49, 3780-7	7.5	74
32	Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. <i>Journal of Medical Economics</i> , 2013 , 16, 691-700	2.4	46
31	Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4587-4587	2.2	5
30	Chromophobe renal cell carcinoma: a review of an uncommon entity. <i>International Journal of Urology</i> , 2012 , 19, 894-900	2.3	67
29	Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 767-75	14.4	37
28	Biological markers of cisplatin resistance in advanced testicular germ cell tumours. <i>Clinical and Translational Oncology</i> , 2012 , 14, 452-7	3.6	7
27	PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE) NCT01280201.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4119-4119	2.2	5
26	PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY. <i>Value in Health</i> , 2011 , 14, A168	3.3	3
25	Non-clear cell advanced kidney cancer: is there a gold standard?. <i>Anti-Cancer Drugs</i> , 2011 , 22 Suppl 1, S9-14	2.4	9
24	Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. <i>European Urology</i> , 2011 , 59, 556-62	10.2	75
23	PCN115 Cost of Skeletal-Related Events (SREs) in Patients with Bone Metastases to solid Tumours Based on the Health Resource Utilisation (HRU) Collected in a Prospective European Multinational Observational Study. <i>Value in Health</i> , 2011 , 14, A455	3.3	6
22	Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1750-6	2.2	101
21	Neuroendocrine Carcinoma 2011 , 2482-2486		
20	Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 751-60	6.1	16
19	Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. <i>Anti-Cancer Drugs</i> , 2010 , 21, 478-86	2.4	45
18	Mixed paratesticular liposarcoma with osteosarcoma elements. <i>Clinical and Translational Oncology</i> , 2010 , 12, 148-9	3.6	3

17	Expression of EGFR, HER-2/neu and KIT in germ cell tumours. <i>Clinical and Translational Oncology</i> , 2010 , 12, 443-9	3.6	11
16	Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. <i>Acta Oncologica</i> , 2009 , 48, 475-7	3.2	8
15	Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. <i>Investigational New Drugs</i> , 2009 , 27, 586-94	4.3	50
14	Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2009 , 7, 96	3.4	1
13	Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1940-7	2.2	109
12	Nuevos tratamientos en los tumores neuroendocrinos gastroenteropancreáticos. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2007 , 54, 51-57		
11	Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer. <i>British Journal of Cancer</i> , 2007 , 96, 178-179	8.7	3
10	Eyelid metastasis from mediastinal teratoma with malignant transformation. <i>Acta Oncologica</i> , 2007 , 46, 1200-1	3.2	1
9	Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 4849-57	12.9	74
8	New drug development in digestive neuroendocrine tumors. <i>Annals of Oncology</i> , 2007 , 18, 1307-13	10.3	18
7	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. <i>British Journal of Cancer</i> , 2006 , 95, 1148-54	8.7	272
6	Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. <i>European Journal of Cancer</i> , 2006 , 42, 1875-80	7.5	131
5	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2006 , 17, 81-7	2.4	3
4	Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. <i>Journal of General Internal Medicine</i> , 2006 , 21, C6-8	4	30
3	Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. <i>Journal of General Internal Medicine</i> , 2006 , 21, 1206-1206	4	2
2	Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. <i>Journal of Neuro-Oncology</i> , 2004 , 66, 345-50	4.8	60
1	Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. <i>Cancer</i> , 2004 , 100, 2462-9	6.4	63